Visible Patient

Visible Patient is pleased to announce the closing of its second fundraising for € 11.3 million (equity financing). Crédit Mutuel Innovation has led this roundtable along with Alsace Creation. This fundraising aims to promote the territorial development of its international offering (Europe, North America and Asia), and to accelerate the development of its new patents for medical image analysis by artificial intelligence.

Visible Patient is a Spinoff from Ircad, located in Strasbourg. The company offers an online medical analysis service to model in 3D the specific anatomy of each patient from his/her CT-scan or MRI images. It also offers software that allows surgeons to simulate an operation and to determine more effectively and safely the best therapeutic choice. Visible Patient software is a class II.A medical device certified for Europe and the United States, based on patented algorithms combining mathematics and artificial intelligence. Thanks to the Visible Patient solution, complications related to anatomical variations can thus be detected preoperatively, making it possible to avoid potential errors, to improve the surgical procedure and, in some cases, to offer a curative surgical solution to patients who seemed ineligible for surgery. More than 3000 patients have already benefited from Visible Patient technology.

The analysis cost is now covered by several French private health insurances such as Assurances Crédit Mutuel or AG2R La Mondiale. They will be followed this year by other major insurances that are already in advanced negotiation with Visible Patient for such coverage. These medical, technological and economic successes explain the fundraising which will enable to accelerate its development for the benefit of patients.

"This fundraising is a key step in the development of our company. It validates our technological and economical choices and recognizes Visible Patient’s results over the last years. I’m thinking of the coverage of our analysis by major private health insurances or our new patented software based on artificial intelligence. Our goal is to give patients worldwide the opportunity to have access to our innovation."
Luc Soler,Cofounder and President of Visible Patient, Associated Professor in the Faculty of Medicine of the Strasbourg University.

"Visible Patient, resulting from 15 years of research at Ircad, definitely makes surgery enter the digital world. The service offered by the start-up consists in reconstructing the patient in 3D from his/her medical image, which allows the surgeon to understand the anatomical details of the organ to be operated, in order to propose targeted and personalized surgery, but also to prepare and simulate the gesture before the surgical procedure. No doubt this tool will become mandatory before any complex surgical procedure. This latest fundraising will allow, especially through enhanced intelligence, to shorten reconstruction time of the medical image to a true digital clone of the patient, and to disseminate this major technological advance around the world."
Jacques Marescaux, Cofounder of Visible Patient, Founder and President of Ircad, Professor at the Strasbourg University Hospital.

"Crédit Mutuel Innovation is very proud to support Visible Patient in a new chapter of its history, alongside the company’s management, its historical shareholders and new financial partners. This partnership between Crédit Mutuel Innovation and Visible Patient is the result of our belief in the relevance of the technology developed by the company. This round of financing will enable the company to implement its ambitious strategic plan and accelerate its international expansion."
Clément Combal, Investment Director, Crédit Mutuel Innovation, a subsidiary of Crédit Mutuel Alliance Fédérale.

Contact us